Overcoming ovarian cancer chemoresistance by CO-targeting senescence and apoptosis

Active Grant Awarded

Award ID
R01CA311522
Recipient
Awarding agency
Obligated
$390,447

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 3% complete
Place of performance
Boston, MA 02115, USA

Award details come from USAspending.gov.

About this award

The National Cancer Institute, within the Department of Health and Human Services' National Institutes of Health, awarded President and Fellows of Harvard College, operating through its Harvard T.H. Chan School of Public Health, $390,447 under Grant R01CA311522 on September 23, 2026. The award falls under the Cancer Treatment Research program (CFDA 93.395).

The award funds preclinical research on overcoming chemoresistance in lethal ovarian cancers, including high-grade serous ovarian cancer (HGSOC). The project will measure apoptotic dependencies in ovarian cancer cells after treatment with frontline and experimental therapies, define the mechanisms underlying those dependencies in HGSOC, and identify signaling pathways linking cellular damage and stress signals in these tumors. Its central hypothesis is that biomarker-guided regimens combining frontline cytotoxic and targeted treatments with BH3 mimetics, especially BCL-XL-targeting agents, will extend remissions. The work uses ovarian cancer cell lines, primary tumors, and laboratory tumor-formation models.

Performance is at Boston, Massachusetts (02115). The period of performance runs from the September 23, 2026 award date to an ultimate completion date of August 31, 2031. The source identifies no sub-recipients for this award.

Description

Abstract
To effectively treat lethal ovarian cancers, including high-grade serous ovarian cancer (HGSOC), and achieve durable remissions and cures, therapies must selectively and potently induce tumor-cell death. Current therapies, particularly the frontline agents carboplatin and paclitaxel, induce ovarian tumor regression and even cure a subset (~15-20%) of patients; however, tumor cells frequently develop treatment resistance, and recurrence is common. Using ovarian cancer cell lines, primary tumors, and laboratory models of tumor formation, we recently found that HGSOC tumors are primed for apoptosis, contributing to their initial sensitivity to frontline therapy. Most ovarian tumors also depend strongly on pro-survival BCL-2 family proteins, particularly BCL-XL, especially after exposure to existing therapies. Notably, HGSOC cells that survive treatment can enter senescence, a highly secretory and nondividing state that may promote chemoresistance in remaining tumor cells; however, these senescent cells also become more sensitive to established senolytic agents, including BCL-XL inhibitors. These findings support a comprehensive preclinical evaluation of combination therapies that exploit apoptotic dependencies using BH3 mimetics, which may extend remissions and increase cure rates by preventing or delaying treatment resistance by eliminating senescent tumor cells. We hypothesize that patients with ovarian cancer will benefit from biomarker-guided precision therapies that combine frontline cytotoxic and targeted treatments with BH3 mimetics, especially agents targeting BCL-XL. To test this hypothesis, we will measure apoptotic dependencies in ovarian cancer cells after treatment with frontline and experimental therapies and define the mechanisms underlying these dependencies in HGSOC. We will also identify signaling pathways that connect cellular damage and stress signals to BCL-2 family proteins at the mitochondria and determine how these pathways promote apoptosis or senescence, and test how therapy-induced senescence contributes to chemotherapy resistance. Our studies will analyze HGSOC patient tumors to measure apoptotic dependencies and the abundance of senescent cells before treatment, after treatment, and at recurrence, and will identify biomarkers that may guide personalized therapy. Finally, we will establish the efficacy of these strategies in patient-derived HGSOC xenograft models in mice, including novel proteolysis-targeting chimeras (PROTACS), which reduce the on-target toxicities associated with first-generation BCL-XL inhibitors while eliminating senescent cancer cells. Limited animal studies are necessary to examine processes that cannot be readily modeled in vitro or studied directly in patients, including effects on vascular endothelial cells and senescent cells that may influence drug delivery, tracking of metastatic growth within the peritoneal cavity, and monitoring for unexpected treatment toxicities. Overall, these studies will advance the development of BH3 mimetics and PROTACS as strategies to prevent treatment resistance and improve cure rates for women with ovarian cancer.

Quick answers

Who received award R01CA311522?

R01CA311522 was awarded to President And Fellows Of Harvard College by National Cancer Institute (National Institutes of Health) on September 23, 2026.

How much is award R01CA311522 worth?

$390,447 has been obligated on R01CA311522.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award